SenzaGen Investor Relations Material
Latest events
Q1 2024
SenzaGen
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from SenzaGen
Access all reports
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers modified human cell lines that can be induced to react with a wide variety of chemicals and cell genes that may be activated by specific substances. SenzaGen AB was incorporated in 2000 and is based in Lund, Sweden. As of February 19, 2016, SenzaGen AB operates as a subsidiary of Ascendis Pharma A/S.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SENZA
Country
🇸🇪 Sweden